International Exchange: Professor Tadashi Motomura, a Cardiovascular Expert from the United States, Visits Shanghai Yida Hospital
On 12 November, Professor Tadashi Motomura, of the Methodist Hospital Research Institute in the United States and the Faculty of Medicine of Fukuoka University in Japan, and head of the EVAHEART clinical trial program in the United States, Professor Tadashi Motomuraand his party visited Yida Hospital, School of Medicine, Shanghai University for exchange, holding an academic symposium on the theme of "Frontier Advances and Applications of Artificial Heart Technology".
Professor Tadashi Motomura is currently a professor at the Faculty of Medicine of Fukuoka University in Japan, and studied under Professor Debakey, who performed the first LVAD operation. Since taking up a professorship at the International Center for Medical Technologies (ICMT) in 2008, he has played an important role in the research, development and clinical application of new medical technologies.
Member of the American Society for Artificial Internal Organs
Member of the American Association for Thoracic Surgery
Member of the Editorial Board of the American Association for Thoracic Surgery - Artificial Organs
Member of the International Society for Heart and Lung Transplantation
At 3 p.m., accompanied by representatives of the hospital, Professor Tadashi Motomura visited the core areas of the hospital, from the display of Party building work and milestones in the central hall exhibition area, to the overall plan for Yuanda Health City in the model display area and discussion of experience at the minimally invasive coronary bypass training base, learning in detail about the hospital's achievements in discipline development and the development of medicine and research.
At the symposium, Academician Wan Feng, discipline leader of the Heart Center, extended a warm welcome to Professor Motomura and his party on behalf of the hospital, and emphasized that Yida Hospital has always kept the patient at the center and is dedicated to providing high-quality medical services; this exchange is a vivid example of the hospital promoting the coordinated development of medicine and research and strengthening high-level international academic cooperation.
Speaking on "the Research, Development and Clinical Application of the EVAHEART Artificial Heart System", Professor Motomura gave a comprehensive analysis of the current state and trends of artificial heart technology from multiple perspectives including hemodynamic design, biocompatible materials, implantation surgical techniques and long-term follow-up data.
Professor Motomura pointed out that as the number of patients with heart failure continues to rise, the artificial heart has become one of the important means of treating end-stage heart failure. With advantages such as low hemolysis and high blood flow compatibility, the new third-generation EVAHEART system has shown good safety and efficacy in international multicenter clinical trials and will bring new hope to patients.
In the academic exchange session, Director Meng Qingzhi, Director Xu Dongjin, Director Wu Xusheng and Director Zhang Jianjun of the Yida Heart Center exchanged views with Professor Motomura on questions such as the coordinated medical and surgical treatment of cardiovascular disease and clinical research. Both sides agreed that the diagnosis and treatment of cardiovascular disease has entered the era of "team-based medicine", and that the deep integration of cardiology and cardiac surgery is the key to raising the overall standard of care.
Bringing together the wisdom of the world to protect human health. In his concluding remarks, Professor Wan Feng pointed out that Professor Motomura's visit had not only brought internationally advanced academic ideas, but had also injected new momentum into the discipline development and international cooperation of the hospital's Heart Center. He said that in the future Yida Hospital will draw on the research platform of School of Medicine, Shanghai University to continue strengthening the integrated development path of "medical care, teaching and research", drive continuous breakthroughs in cardiovascular diagnostic and treatment technology, and contribute to building a "Healthy China".